Literature DB >> 15868410

Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration.

T Sadowski1, S Dietrich, F Koschinsky, A Ludwig, E Proksch, B Titz, R Sedlacek.   

Abstract

In this study we analyzed the proteolytic activity of MMP-19 and its impact on keratinocyte migration. In the HaCaT keratinocyte cell line overexpressing wild-type MMP-19 (HaCaT-WT), transmigration through fibrin and type IV collagen matrices was significantly increased compared to cells harboring a catalytically inactive mutant (HaCaT-EA). Studying the expression of MMP-19 in early stages of squamous cell cancer (SCC), we found co-localization of MMP-19 and laminin 5 at the invading tumor front but not in suprabasal epidermis of the tumor. Examination of laminin 5 processing revealed increased processing of the gamma2 chain in the medium and matrix of HaCaT-WT cells and degradation by recombinant human MMP-19 to 105-kDa and 80-kDa fragments. Parental HaCaT grown on the matrix of HaCaT-WT and HaCaT-EA cells displayed differential tyrosine phosphorylation. Using integrin blocking and stimulating antibodies we could attribute these differences to a shift from beta4-integrin-dependent signaling on the HaCaT-EA matrix toward alpha3-integrin-dependent signaling on the HaCaT-WT matrix. As a consequence, parental HaCaT showed increased migration on the matrix of HaCaT-WT cells. These data suggest that the MMP-19-dependent processing of the gamma2 chains leads to the integrin switch favoring epithelial migration and that MMP-19 actively participates in the early stages of SCC invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868410     DOI: 10.1007/s00018-005-4478-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  15 in total

1.  Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial.

Authors:  Mark H Drazner; Anne S Hellkamp; Carl V Leier; Monica R Shah; Leslie W Miller; Stuart D Russell; James B Young; Robert M Califf; Anju Nohria
Journal:  Circ Heart Fail       Date:  2008-09       Impact factor: 8.790

2.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.

Authors:  Cynthia Binanay; Robert M Califf; Vic Hasselblad; Christopher M O'Connor; Monica R Shah; George Sopko; Lynne W Stevenson; Gary S Francis; Carl V Leier; Leslie W Miller
Journal:  JAMA       Date:  2005-10-05       Impact factor: 56.272

3.  Longitudinal BNP follow-up as a marker of treatment response in acute heart failure: Relationship with objective markers of decongestion.

Authors:  Hesham R Omar; Maya Guglin
Journal:  Int J Cardiol       Date:  2016-06-27       Impact factor: 4.164

4.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

5.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study.

Authors:  R Kazanegra; V Cheng; A Garcia; P Krishnaswamy; N Gardetto; P Clopton; A Maisel
Journal:  J Card Fail       Date:  2001-03       Impact factor: 5.712

6.  Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.

Authors:  Friedrich M Fruhwald; Astrid Fahrleitner-Pammer; Rudolf Berger; Francisco Leyva; Nick Freemantle; Erland Erdmann; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi; Jean-Claude Daubert; John G F Cleland
Journal:  Eur Heart J       Date:  2007-02-13       Impact factor: 29.983

7.  In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study.

Authors:  Salvatore Di Somma; Laura Magrini; Valerio Pittoni; Rossella Marino; Antonella Mastrantuono; Enrico Ferri; Paola Ballarino; Andrea Semplicini; Giuliano Bertazzoni; Giuseppe Carpinteri; Paolo Mulè; Maria Pazzaglia; Kevin Shah; Alan Maisel; Paul Clopton
Journal:  Crit Care       Date:  2010-06-16       Impact factor: 9.097

8.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

9.  Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.

Authors:  Alain Cohen-Solal; Damien Logeart; Bidan Huang; Danlin Cai; Markku S Nieminen; Alexandre Mebazaa
Journal:  J Am Coll Cardiol       Date:  2009-06-23       Impact factor: 24.094

10.  A single BNP measurement in acute heart failure does not reflect the degree of congestion.

Authors:  Hesham R Omar; Maya Guglin
Journal:  J Crit Care       Date:  2016-03-08       Impact factor: 3.425

View more
  26 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Ectoplasmic specialization: a friend or a foe of spermatogenesis?

Authors:  Helen H N Yan; Dolores D Mruk; Will M Lee; C Yan Cheng
Journal:  Bioessays       Date:  2007-01       Impact factor: 4.345

Review 4.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

Review 5.  Laminin-332-integrin interaction: a target for cancer therapy?

Authors:  Daisuke Tsuruta; Hiromi Kobayashi; Hisayoshi Imanishi; Koji Sugawara; Masamitsu Ishii; Jonathan C R Jones
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 6.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 7.  Bioactive extracellular matrix fragments in lung health and disease.

Authors:  Amit Gaggar; Nathaniel Weathington
Journal:  J Clin Invest       Date:  2016-09-01       Impact factor: 14.808

8.  [Expression of matrix metalloproteinase-19 in the human cornea. Wound healing in the MMP-19 knock-out mouse model].

Authors:  F Treumer; C Flöhr; A Klettner; B Nölle; J Roider
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

Review 9.  Mechanisms mediating the vesicant actions of sulfur mustard after cutaneous exposure.

Authors:  Michael P Shakarjian; Diane E Heck; Joshua P Gray; Patrick J Sinko; Marion K Gordon; Robert P Casillas; Ned D Heindel; Donald R Gerecke; Debra L Laskin; Jeffrey D Laskin
Journal:  Toxicol Sci       Date:  2009-10-15       Impact factor: 4.849

10.  Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

Authors:  Sharon J Pitteri; Lellean JeBailey; Vitor M Faça; Jason D Thorpe; Melissa A Silva; Reneé C Ireton; Marc B Horton; Hong Wang; Liese C Pruitt; Qing Zhang; Kuang H Cheng; Nicole Urban; Samir M Hanash; Daniela M Dinulescu
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.